{
    "code": "02022442",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02022442",
    "time": "2016-03-18 04:18:39",
    "許可證字號": "衛署藥輸字第022442號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "108\/04\/06",
    "發證日期": "88\/04\/06",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202244208",
    "中文品名": "德爾胰錠５公絲",
    "英文品名": "DAONIL TABLETS 5MG",
    "適應症": "糖尿病。",
    "劑型": "110錠劑",
    "包裝": "鋁箔盒裝",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "主成分略述": "GLYBURIDE (EQ TO GLIBENCLAMIDE)",
    "限制項目": [
        "02輸入"
    ],
    "申請商名稱": "1424601100  賽諾菲股份有限公司",
    "申請商地址": "台北市信義區松仁路3號7樓",
    "主製造廠": {
        "製造廠名稱": "F270063000  HANDOK INC.",
        "製造廠廠址": "78, DAEPUNGSANDAN-RO, DAESO-MYEON, EUMSEONG-GUN, CHUNGCHEONGBUK-DO, KOREA",
        "製造廠公司地址": "735,YOKSAM-I-DONG KANGNAM-KU,SEOUL ,KOREA",
        "製造廠國別": "KOREA",
        "製程": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses,put up in measured doses or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "6820600700",
            "成分名稱": "GLYBURIDE (EQ TO GLIBENCLAMIDE)",
            "含量描述": "",
            "含量": "5.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "白色",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "長圓柱形",
        "標記一": "LDI,",
        "標記二": "LDI,安萬特1"
    },
    "藥物辨識外觀圖片": [
        {
            "title": "圖片",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022442&Seq=435&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "020224420001-104-06-02.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022442&Seq=004&Type=9"
        },
        {
            "title": "Daonil 5mg_leaflet_E_CCDS v7_approved-103-10-01.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022442&Seq=003&Type=9"
        },
        {
            "title": "Daonil 5mg_leaflet_C_CCDS v7_approved-103-10-01.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022442&Seq=002&Type=9"
        },
        {
            "title": "020224420001.jpg",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022442&Seq=001&Type=9"
        },
        {
            "title": "020224420002.jpg",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022442&Seq=002&Type=8"
        },
        {
            "title": "020224420001.jpg",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022442&Seq=001&Type=8"
        }
    ]
}